Entacapone in the management of Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 957-963

  Henchcliffe, Claire ^a   Waters, Cheryl ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

COMT inhibitor; Entacapone; Motor fluctuations; Parkinson's disease

Indexed keywords

6 FLUORODOPA F 18; ADRENALIN; AMANTADINE; APOMORPHINE; BENSERAZIDE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; EPHEDRINE; HYDRALAZINE; IMIPRAMINE; ISOPRENALINE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; TOLCAPONE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; ENZYME INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSKINESIA; HUMAN; HYPERTENSION; HYPOTENSION; LIVER FUNCTION; MOTOR DYSFUNCTION; PARKINSON DISEASE; SIDE EFFECT; BLOOD; DRUG ANTAGONISM; DRUG COMBINATION; METABOLISM; REVIEW;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; CATECHOLS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMAN; LEVODOPA; PARKINSON DISEASE; HUMANS;

EID: 0035987750     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.957     Document Type: Article

References (47)

1. Epidemiology of Parkinson's disease
2. Biochemical aspects of Parkinson's disease
3. Recent advances in the genetics and pathogenesis of Parkinson's disease
4. Comparative tolerability of the newer generation antiparkinsonian agents
5. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease
6. Practical issues with COMT inhibitors in Parkinson's disease
7. Tolcapone: COMT inhibition for the treatment of Parkinson's disease
8. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
9. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
10. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients
11. Clinical pharmacokinetics of anti-parkinsonian drugs
12. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition
13. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine
14. Problems associated with long-term levodopa treatment of Parkinson's disease
15. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
16. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease
17. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyl-transferase inhibitor, in man - A study using a stable isotope technique
18. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
19. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers
20. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
21. Entacapone in combination with standard or controlled-release levodopa/carbidopa: A clinical and pharmacokinetic study in patients with Parkinson's disease
22. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
23. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
24. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
25. The UPDRS Development Committee: Unified Parkinson's disease Rating Scale
26. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
27. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
28. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
29. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
30. Levodopa: Rational and irrational pharmacology
31. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease
32. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction
33. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging
34. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
35. Pharmacokinetics, pharmacodynamics and tolerability of tolcapone: A review of early studies in volunteers
36. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients
37. Twelve-month safety of entacapone in patients with Parkinson's disease
38. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions
39. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers
40. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease
41. Entacapone and selegiline with L-dopa in patients with Parkinson's disease: An interaction study
42. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise
43. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-dopa-treated patients with Parkinson's disease
44. Twelve-month safety of entacapone in patients with Parkinson's disease
45. Severe hypertension following ephedrine administration in a patient receiving entacapone
46. Hallucinosis in idiopathic Parkinson's disease
47. Cost-effectiveness analysis of entacapone in Parkinson's disease: A Markov process analysis